New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
10:00 EDTEWEdwards Lifesciences rises 5.9%
Edwards Lifesciences is up 5.9%, or $4.66, to $83.10
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 13, 2015
19:23 EDTEWEdwards Lifesciences holders should expect gains from acquisition, Barron's says
Edwards Lifesciences acquired CardiAQ and received two upgrades; shareholders should expect more gains, despite the stock's expensive price, Barron's contends in its 'Barron's Take' column. Reference Link
10:21 EDTEWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:41 EDTEWEdwards Lifesciences upgraded to Outperform from Market Perform at Northland
Northland upgraded Edwards Lifesciences to Outperform citing the acquisition of CardiAQ, an early-stage company developing a TMVI system. The firm views the acquisition as a smart as it jump starts the TMVI program and adds a wealth knowledge from the principals who have a prior background at CoreValue. Northland increased Edwards Lifesciences' price target to $170 from $140 on shares.
07:48 EDTEWCanaccord recommends Edwards Lifesciences, Neovasc in TMVR sector
Canaccord said they continue to like both Edwards Lifesciences (EW) and Neovasc (NVCN) in the transcatheter mitral valve replacement, or TMVR, space. The firm sees long term growth potential in the TMVR space and upside earnings and revenue potential in Edwards due to its leverage there and its acquisition of privately held CardiAQ. The firm said the removal of CardiAQ as a competitor should be positive for Neovasc and has a Buy rating on both stocks.
07:02 EDTEWEdwards Lifesciences upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use